ocr: Figure 2: Cumulative Percentage of Patients Completing 26 Weeks of Double-blind Treatment with Specified Changes from Baseline ADAS-cog Scores. The Percentages of Randomized Patients who Completed the Study were: Placebo 84%, 1-4 mg 85%, and 6-12 mg 65%. 100 A - 90 a l 9 E a 00 : d - à - . Bertd - - * e 4 > 80 a 70 a - 60 U 2 50 a Change in ADAS-cog 40 -0-6 6-12 mg Treatment Group -7 4 4 0 S 30 - 1-4mg Placebo 1.6 6.8 26.5 20 - 1 A Placebo 1-4 mg/day 2.0 11.8 34.5 6-12 mg/day 11.7 24.8 55.8 10 Totop -25 - : - -20 -15 - -10 -5 0 5 10 15 20 25 30 Change From Baseline
